Ipsen Limited

Ipsen U.K. and Ireland is a core part of Ipsen’s global biopharmaceutical business and is driven by the belief that patients don’t have time to wait.

Our licensed medicines and R&D are all focused on improving quality of life and relieving suffering, hoping to bring real value to the healthcare community along every step of the treatment pathway. We push ourselves to address the most complex and difficult issues facing people’s health to deliver better outcomes. This purpose driven approach ensures we deliver real impact, in a sustainable way, for patients and society.

Ipsen works across a diverse oncology portfolio in the U.K. and Ireland, which includes prostate cancer, neuroendocrine tumours, renal cell carcinoma, hepatocellular carcinoma and thyroid cancer.

ALLSC-UK-001850 | January 2025